透析患者的高血压:欧洲肾脏与心血管医学工作组及欧洲高血压与肾脏工作组的共识文件
该共识文件由欧洲肾脏与心血管医学(EURECA-m)工作组与欧洲高血压与肾脏工作组联合制定,概述透析患者高血压的诊断、流行病学、发病机制和治疗。文件指出家庭或动态血压监测发现血压升高与生存期缩短明确相关,钠和容量过多是主要机制,非药物治疗是基础,必要时使用降压药。
要点
- 透析患者高血压常见且常控制不佳,家庭或动态血压监测发现血压升高与生存期缩短明确相关。
- 钠和容量过多是透析患者高血压的主要机制,非药物干预 targeting 钠和容量过多是控制基础。
- 充分处理钠和容量过多后血压仍高时需使用降压药,选药需考虑合并症和药物可透析性。
核心结论
- 透析患者高血压常见且常控制不佳,钠和容量过多是主要机制,非药物干预是基础,必要时使用降压药。
研究设计与样本
- 欧洲肾脏与心血管医学(EURECA-m)工作组与欧洲高血压与肾脏工作组联合制定的共识文件。
主要发现
- 透析前或透析后血压记录与心血管事件和生存呈J形或U形关联,可能反映测量准确性低和透析相关血流动力学特点。
- 家庭或动态血压监测检测到的血压升高与较短生存期明确相关。
- 钠和容量过多是透析患者高血压的主要机制,动脉僵硬度、肾素-血管紧张素-醛固酮和交感神经系统激活、内皮功能障碍、睡眠呼吸暂停和促红细胞生成素刺激剂使用也可能参与。
临床怎么用
- 非药物干预 targeting 钠和容量过多是透析患者高血压控制的基础。
- 充分处理钠和容量过多后血压仍升高时,需要使用降压药物。
- 透析人群药物治疗应考虑患者合并症和每种药物的具体特征,如可透析性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In patients with end-stage renal disease (ESRD) treated with haemodialysis or peritoneal dialysis, hypertension is common and often poorly controlled. Blood pressure (BP) recordings obtained before or after haemodialysis display a J- or U-shaped association with cardiovascular events and survival, but this most likely reflects the low accuracy of these measurements and the peculiar haemodynamic setting related to dialysis treatment. Elevated BP detected by home or ambulatory BP monitoring is clearly associated with shorter survival. Sodium and volume excess is the prominent mechanism of hypertension in dialysis patients, but other pathways, such as arterial stiffness, activation of the renin-angiotensin-aldosterone and sympathetic nervous systems, endothelial dysfunction, sleep apnoea and the use of erythropoietin-stimulating agents may also be involved. Non-pharmacologic interventions targeting sodium and volume excess are fundamental for hypertension control in this population. If BP remains elevated after appropriate treatment of sodium and volume excess, the use of antihypertensive agents is necessary. Drug treatment in the dialysis population should take into consideration the patient's comorbidities and specific characteristics of each agent, such as dialysability. This document is an overview of the diagnosis, epidemiology, pathogenesis and treatment of hypertension in patients on dialysis, aiming to offer the renal physician practical recommendations based on current knowledge and expert opinion and to highlight areas for future research.
引用
- Sarafidis PA, Persu A, Agarwal R, et al. Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH). Nephrol Dial Transplant. 2017. PMID: 28340239. doi:10.1093/ndt/gfw433
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。